|
|
Post by awesomo on Jan 6, 2022 11:59:47 GMT -5
If I learned nothing else from being a stocker holder of drug and medical device companies, the key take away is that it takes multiple years of research, clinical trials, and regulatory approvals to get a product out the door and gain traction in the marketplace. From product concept to entering Phase I trials (RLS) in 5 years doesn’t seem too unreasonable. I'd agree with you if there was anything remotely tangible on the horizon with RLS. Just a lot of smoke and mirrors so far. It could be another 5, 10 years, or never. |
|
|
|
Post by cretin11 on Jan 6, 2022 13:25:28 GMT -5
Yeah, boca, gotta agree that there’s not much (is there anything?) to hang our hat on regarding RLS. We can say it takes five years to get there, but when the five years goes by and we have nothing tangible, it’s more hopium than reality based. Would love to be pleasantly surprised by RLS.
|
|
|
|
Post by boca1girl on Jan 6, 2022 13:59:48 GMT -5
Yeah, boca, gotta agree that there’s not much (is there anything?) to hang our hat on regarding RLS. We can say it takes five years to get there, but when the five years goes by and we have nothing tangible, it’s more hopium than reality based. Would love to be pleasantly surprised by RLS. I DID NOT SAY “that there’s not much to hang our hat on regarding RLS”. That is your statement, not mine. I DO NOT agree with your statement. |
|
|
|
Post by Clement on Jan 6, 2022 14:03:43 GMT -5
Here's a news item From August about RLS103 dry powder CBD for panic. Indicates progress. www.oindpnews.com/2021/08/positive-phase-1-results-for-receptor-life-sciences-rls103-cbd-dpi/Receptor Life Sciences (RLS) has published data from a Phase 1 PK trial of its RLS103 dry powder cannabidiol (CBD) in the Journal of Pharmaceutical Sciences demonstrating significantly greater bioavailability for the inhaled CBD than for Epidiolex oral CBD solution. RLS announced completion of its pre-IND meeting with the FDA in January 2021. |
|
|
|
Post by markado on Jan 6, 2022 14:04:19 GMT -5
If I learned nothing else from being a stocker holder of drug and medical device companies, the key take away is that it takes multiple years of research, clinical trials, and regulatory approvals to get a product out the door and gain traction in the marketplace. From product concept to entering Phase I trials (RLS) in 5 years doesn’t seem too unreasonable. And, provided the classification for Cannabis, Cannabis Sativa and CBD pre state level legalization and the farm bill, no one would touch it, as it could invalidate your drug manufacturer's license with the FDA - even just having the raw ingredient on site, let alone potentially violating state laws transporting raw ingredients across state lines. Taking all of that into account, and the current 505b pathway for multiple indications, I would consider RLS in 3rd gear. |
|
|
|
Post by mango on Jan 6, 2022 14:12:27 GMT -5
I don’t have any problem with the Wainright conference but wish it was a bigger player. MC doesn’t have any responsibility for LQDA or it’s new CEO. MNKD did everything right for TreT approval, UTHR dropped the ball with the 3rd party test house. I want more transparency from MNKD. Maybe there is a CDA in place with Thirono that prevents disclosure, but would like to know. He doesn't have responsibility for LQDA, but he does have responsibility for the shareholders. The Wainwright conference is just kicking the tires like usual, and using MannKind funds for a board seat on a nothing pharma company? Not a good look. Just to play devil’s advocate…what if they have something valuable here? We’ll see the preclinical data in 2Q. My guess is they have additional compounds that we want, which is why MC got the seat. A long term partnership. Just a thought. |
|
|
|
Post by awesomo on Jan 6, 2022 14:29:33 GMT -5
He doesn't have responsibility for LQDA, but he does have responsibility for the shareholders. The Wainwright conference is just kicking the tires like usual, and using MannKind funds for a board seat on a nothing pharma company? Not a good look. Just to play devil’s advocate…what if they have something valuable here? We’ll see the preclinical data in 2Q. My guess is they have additional compounds that we want, which is why MC got the seat. A long term partnership. Just a thought. I'll have to see it to believe it. If there isn't concrete details, milestones, etc., MannKind's partnerships have been all fluff. The Thirona CEO doesn't even list Thirona on his LinkedIn profile... J Gordon Foulkes - CEO - Lipidio Pharmaceuticals Inc | LinkedIn |
|
|
|
Post by cretin11 on Jan 6, 2022 14:58:01 GMT -5
Yeah, boca, gotta agree that there’s not much (is there anything?) to hang our hat on regarding RLS. We can say it takes five years to get there, but when the five years goes by and we have nothing tangible, it’s more hopium than reality based. Would love to be pleasantly surprised by RLS. I DID NOT SAY “that there’s not much to hang our hat on regarding RLS”. That is your statement, not mine. I DO NOT agree with your statement. To be clear, it was NOT your statement, it was me agreeing with awesomo’s statement. Sorry for the ambiguity there. I hope you end up being correct about RLS, but at this point there’s not much to hang our hats on, after all these years. |
|
|
|
Post by prcgorman2 on Jan 6, 2022 20:31:20 GMT -5
If I learned nothing else from being a stocker holder of drug and medical device companies, the key take away is that it takes multiple years of research, clinical trials, and regulatory approvals to get a product out the door and gain traction in the marketplace. From product concept to entering Phase I trials (RLS) in 5 years doesn’t seem too unreasonable. I'd agree with you if there was anything remotely tangible on the horizon with RLS. Just a lot of smoke and mirrors so far. It could be another 5, 10 years, or never. Hmm, I agree with being skeptical, but the reason I show respect is because of who RLS acquired from Mannkind to work on their compounds and because Paul Allen’s money funded them. These people are not fly-by-night. I just don’t understand how people can be so dismissive of every move Dr. Castagna makes, especially when I look at what he started with and when I look at the debt and share price now after his leadership for 4 years. I half-expected bankruptcy and utter ruin. Nobody even talks about that anymore. Why? Because we have an over-achiever CEO who annexed his PharmaD while he was rescuing Mannkind from the cliff’s edge disaster they were still reeling from after the Sanofi perfidy. Cripes. Which one of any of the people who post here could have done as well? Not me. And given the shallow thinking of many of the detractors, I don’t think any of them either. |
|
|
|
Post by sportsrancho on Jan 6, 2022 21:34:38 GMT -5
Paul Allen funded them?
|
|
|
|
Post by awesomo on Jan 6, 2022 23:54:40 GMT -5
I'd agree with you if there was anything remotely tangible on the horizon with RLS. Just a lot of smoke and mirrors so far. It could be another 5, 10 years, or never. Hmm, I agree with being skeptical, but the reason I show respect is because of who RLS acquired from Mannkind to work on their compounds and because Paul Allen’s money funded them. These people are not fly-by-night. I just don’t understand how people can be so dismissive of every move Dr. Castagna makes, especially when I look at what he started with and when I look at the debt and share price now after his leadership for 4 years. I half-expected bankruptcy and utter ruin. Nobody even talks about that anymore. Why? Because we have an over-achiever CEO who annexed his PharmaD while he was rescuing Mannkind from the cliff’s edge disaster they were still reeling from after the Sanofi perfidy. Cripes. Which one of any of the people who post here could have done as well? Not me. And given the shallow thinking of many of the detractors, I don’t think any of them either. There’s nothing that definitely ties Paul Allen to RLS so stop spreading misinformation. It’s all speculation. And even if a fund of his is tied to it, these people put their money in hundreds of investments hoping for a few home runs while the majority fail. Also, Castagna is an over achieving CEO? Rest and grow guy? 😂 |
|
|
|
Post by prcgorman2 on Jan 7, 2022 7:37:16 GMT -5
Hmm, I agree with being skeptical, but the reason I show respect is because of who RLS acquired from Mannkind to work on their compounds and because Paul Allen’s money funded them. These people are not fly-by-night. I just don’t understand how people can be so dismissive of every move Dr. Castagna makes, especially when I look at what he started with and when I look at the debt and share price now after his leadership for 4 years. I half-expected bankruptcy and utter ruin. Nobody even talks about that anymore. Why? Because we have an over-achiever CEO who annexed his PharmaD while he was rescuing Mannkind from the cliff’s edge disaster they were still reeling from after the Sanofi perfidy. Cripes. Which one of any of the people who post here could have done as well? Not me. And given the shallow thinking of many of the detractors, I don’t think any of them either. There’s nothing that definitely ties Paul Allen to RLS so stop spreading misinformation. It’s all speculation. And even if a fund of his is tied to it, these people put their money in hundreds of investments hoping for a few home runs while the majority fail. Also, Castagna is an over achieving CEO? Rest and grow guy? 😂 As I recall, it was the lawer CEO and the law firm that tied RLS to the Paul Allen funds. I agree it was speculation, but is not just random disinformation. And yes, absolutely, VC is given to lots of R&D efforts with the assumption a few will be home runs. So what? Ever tried to get VC? It ain’t like on Shark Tank which is a joke. But you’re also making the point for me that there isn’t any reason to scoff and be dismissive of Thirona Bio just because they list an attorney’s office as their address. These deals are not done by children. They are purposeful and part of a strategy. I remember seeing posts deriding Dr. Castagna for being so single-mindedly focused on re-launching and marketing Afrezza, which was unfair because that’s what Pfeffer said was the reason they hired him! So he discharged his duties as best he could with the shards and shreds he was handed. Afrezza prescriptions have stalled during COVID, but the fact that they have not significantly declined says something good. And, the trajectory was slow, but the trend was positive, and the revenue is material and has helped sustain Mannkind. Now that they’ve returned to the strategy the company was founded for, which is finding and developing therapeutic compounds of value that ride well on TechnoSphere, every move in that direction meets with scoffing and derision. These decisions aren’t done by Dr. Castagna sitting at his desk doing Google searches for likely candidates. These are measured moves. They don’t have the luxury of just throwing money and darts at possible wins. Save the scoffing and derision until after there has been time to determine that a move wasn’t wise. Even RLS doesn’t yet deserve that. Drug development in the U.S. is for patient investors. If you’re antsy, MNKD is maybe not where you should be putting your money. And, that’s OK. That’s not a criticism. Sell and move on to investments where you don’t feel inclined to denigrate the management of the company. |
|
|
|
Post by cretin11 on Jan 7, 2022 10:40:04 GMT -5
So prcgorman now you’re telling awesomo what to do with his MNKD shares. Because you don’t like that he dares to post objective criticism of questionable management moves? That’s presumptuous of you.
Last I checked, there’s no rule that every post here must be of the cheerleading nature. What value would that be anyway? You telling awesomo to sell his shares would be like someone telling you to stay off this message board if you can’t handle opinions that aren’t lockstep with yours.
Thank you to all who post here as long as they are being honest with their opinions. Some will prove to be more right than others, as time goes on. That’s the nature of any healthy message board, we don’t need censorship of legit opinions.
|
|
|
|
Post by sweedee79 on Jan 7, 2022 10:41:21 GMT -5
The Afrezza numbers are about the same.. but we are churning ... As many that start on Afrezza quit Afrezza due to the fact that there is a learning curve with using it.. that isn't good marketing.. it does a lot of damage to the reputation of the drug..
Some here are trying to keep it real.. we can't just deny the problems and spend millions on marketing and not address the underlying issues... And just because he has a doctorate doesn't make him a good CEO..
|
|
|
|
Post by cretin11 on Jan 7, 2022 10:45:10 GMT -5
If anything, prc you stating that Paul Allen funded RLS is the type of post that should be censored, because it’s playing fast and loose with the facts. Or at least show us proof that it’s true, because IF it is true then it’s certainly important info and I’d retract my first sentence here.
|
|
